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We report the rational design of a DNA-binding peptide construct composed of the DNA-contacting
regions of two transcription factors (GCN4 and GAGA) linked through an AT-hook DNA anchor. The
resulting chimera, which represents a new, non-natural DNA binding motif, binds with high affinity and
selectivity to a long composite sequence of 13 base pairs (TCAT-AATT-GAGAG).Transcription Factors (TFs) are specialized proteins that bind to
specic DNA regulatory sequences,1 and thereby promote or
inhibit the transcription of particular genes.2 The recognition
process typically requires the cooperative action of several
modules, which are connected either in a covalent or non-
covalent way. This natural strategy allows the recognition of
relatively large DNA sites, which is fundamental to ensure the
selective targeting of specic genes.3 Thus, the bZIP or bHLH
families bind DNA in the form of leucine zipper-mediated
homo- or heterodimers,4 and the Cys2His2 zinc nger TFs
present multiple recognition modules that simultaneously
interact with consecutive sites along the DNA major groove.5
Other TFs, such as the cro repressor, or the glucocorticoid
nuclear receptor protein, interact to DNA as non-covalent
dimers, inserting recognition helices in the same face of adja-
cent major grooves.6
Over the last few decades there have been many efforts to
develop miniaturized synthetic DNA binders that reproduce the
DNA recognition properties of these natural proteins;7,8 some of
them have even shown potential for the articial control of gene
expression.9 Most designed DNA-binding peptides rely on the
modication of monomeric DNA binding domains,10 or in the
articial dimerization of bZIP basic regions.11 Our group has
demonstrated that appropriate conjugation of monomeric
fragments of transcription factors with small DNA-binding
agents, such as distamycin or pentamidine derivatives,12 or with
short AT-hook peptide motives,13 also leads to high-affinity and
selective DNA binders. However, these binary articialica Biolo´xica e Materiais Moleculares
ga´nica, Universidade de Santiago de
la, Spain. E-mail: joseluis.mascarenas@
76541-14405
(ESI) available: Peptide synthesis, full
data of the peptides and productsconstructs allow the specic recognition of relatively short
stretches of DNA (up to of 9 base pairs), far from the typical
extended DNA sites covered by the natural counterparts.3b This
represents a serious limitation for future applications in the
selective targeting of specic genes. While the desired targeting
of long DNA sites has been successfully achieved by recombi-
nant oligomeric zinc ngers,14 we are not aware of synthetic
peptide constructs that address extended sites by using TF-
based DNA binding modules. Dervan's polyamides are capable
of targeting up to sixteen contiguous base pairs, however they
interact to the DNA through the minor groove.15
Inspired by proteins like the cro repressor, we explored the
possibility of achieving a selective recognition of relatively long
DNA sites by a composite “miniprotein” designed to insert TF
recognition fragments into two consecutive major grooves
(Fig. 1). Herein we demonstrate that covalent tethering of
monomeric TF fragments through a polyglycine linker does not
produce effective binders. However, if the linkage is carried out
by an AT-hook module, the resulting construct binds with high
affinity and specicity to an extended consensus sequenceFig. 1 Cartoon representing the goal of this research, namely the
recognition of extended DNA sites by inserting the basic region (BR) of
GCN4 and the GAGA Zf in adjacent major grooves, and along one face
of the double helix. The question mark intends to indicate the
unknown nature of the connection that could allow the desired
recognition.
This journal is © The Royal Society of Chemistry 2016
Scheme 2 Strategy used for the synthesis of the GCN4/Gly9/GAGA
chimera, BR(Gly9)GAGA, by chemoselective modification of the GAGA
Cys2His2 peptide in solution.
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View Article Onlinespanning 13 bp (TCAT$AATT$GAGAG). This conjugate repre-
sents the rst synthetic peptide chimera capable of binding
specic DNA sites in a tripartite (major–minor–major groove)
manner, and provides a novel DNA binding architecture that
lacks natural counterparts.
As constituent TF fragments, we selected the basic region
(BR) of the yeast GCN4 bZIP protein, and the zinc nger of the
GAGA factor of Drosophila melanogaster, which are both unable
to bind to their target DNA sites as isolated monomers. In the
case of GCN4, we chose the sequence between residues Asp226
and Gln248, which has been identied as the smallest peptide
that retains specic DNA recognition properties when pre-
sented as a dimer,11a,16 or as a stapled derivative.17 With respect
to GAGA, we chose a truncated 31-residue peptide of its zinc
nger region (residues Ser28 to Phe58) that is non functional as
an isolated peptide, but can bind to the DNA when conjugated
to small DNA-binding agents.18
Using as reference the X-ray structures of the GCN4–DNA19
and GAGA–DNA complexes,20 we built a model for the simul-
taneous interaction of the GCN4 basic region and the GAGA zinc
nger in contiguous DNA major grooves covering the same face
of the DNA double helix (see the ESI†). Inspection of this coarse
model suggested that the Arg245 in GCN4, and the Arg44 in
GAGA could be suitable positions for tethering both DNA
binding domains, and that the distance between both domains,
of about 17 A˚, could be effectively satised by a peptidic linker
composed of nine glycines. Aer completing the solid-phase
synthesis of the GCN4 basic region, the connector bearing a Gly9
linker was introduced through an orthogonally-deprotected Lys
side chain that replaces the natural Arg245. We then added
a bromoacetyl moiety that provides a reactive site for coupling
the GAGA peptide fragment (Scheme 1).Scheme 1 Strategy used for the synthesis of the GCN4/Gly9 chimera
BR(Gly9)-Br. The 4-acetamidobenzoic acid (Aba) chromophore is
introduced at the N-terminus of the GCN4 basic region as a spectro-
scopic reporter. O1Pen: 5-amino-3-oxapentanoic acid.
This journal is © The Royal Society of Chemistry 2016The resulting peptide BR(Gly9)-Br was isolated in an
approximate 20% yield aer standard cleavage and HPLC
purication. The GAGA fragment was engineered to incorporate
a Cys residue in the side chain of Lys44 (which replaces the
native Arg). The expected peptide GAGA-SH was obtained in
good yield aer the standard deprotection/resin cleavage step
(Scheme 2). The key coupling reaction between the two peptide
fragments was carried out by dissolving the peptideGAGA-SH in
phosphate buffer at pH 7.5 in presence of 1.5 equiv. of ZnSO4,
and 2 equiv. of BR(Gly9)-Br (see the ESI†). Aer 1 h at room
temperature, we obtained the desired conjugate BR(Gly9)GAGA
in an approximate 45% yield. The chemoselectivity of this
reaction (only the Cys in the side chain of Lys44 is modied, and
no alkylation of Cys36 and Cys39 is observed) stems from the
coordination of the Zn cation by these other two Cys that
support the zinc nger fold.21
With the conjugate at hand, we analyzed its DNA binding
properties using standard non-denaturing EMSA assays in
polyacrylamide gel, and double-stranded (ds) oligonucleotides
featuring composite sites comprising the GCN4 basic region
and the GAGA Zf target sequences separated by four (dsDNA A
and B), or ve base pairs (dsDNA C). These particular base pair
spacers were selected so that the interaction of both binding
regions of the conjugate could take place through the same face
of the DNA double helix. As shown in Fig. 2, incubation of these
dsDNAs with BR(Gly9)GAGA failed in all cases to rise stable DNA
peptide complexes, and we observed only faint slow-migrating
bands that suggest the formation of low affinity complexes.
Although these poor results would advice against further
pursuing this approach to achieve the desired bipartite major
groove binding, we envisioned that using an AT-hook peptide
instead of the (Gly9) connector might allow the formation of
more stable DNA complexes. AT-hookmotives are cationic short
peptides present in HMG-I(Y) eukaryotic nuclear proteins that
feature a central Arg–Gly–Arg core capable of deeply inserting in
the minor groove of AT-rich sites.22 We reasoned that these
peptides, in addition to providing stabilizing contacts with the
DNA, might work as minor groove anchors to ensure the correct
delivery of the TF fragments to their consensus sites.13Chem. Sci., 2016, 7, 3298–3303 | 3299
Fig. 2 DNA binding studies of BR(Gly9)GAGA by EMSA. In all cases,
lanes 1–4: [BR(Gly9)GAGA] ¼ 0, 400, 600, 800 nM with (a) 75 nM of
dsDNA A. (b) with 75 nM of dsDNA B. (c) with 75 nM of dsDNA C.
Oligonucleotide sequences (only one strand shown): A 50-CGCG
TCATAATTGAGAG CGC-30; B 50-CGCG TCATCAGCGAGAG CGC-30;
C 50-CGCG TCATAAATTGAGAG CGC-30. Experiment was resolved by
PAGE on a 10% nondenaturing polyacrylamide gel and 0.5 TBE buffer
over 40 min at rt, and analyzed by staining with SyBrGold (Molecular
Probes: 5 mL in 50 mL of 1 TBE) for 10 min, followed by fluorescence
visualization.
Fig. 3 EMSA DNA binding studies of BR(Hk)GAGA. In all cases, lanes
1–4: [BR(Hk)GAGA] ¼ 0, 400, 600, 800 nM with (a) 75 nM of dsDNA A;
(b) 75 nM of dsDNA D; (c) 75 nM of dsDNA E; (d) 75 nM of dsDNA B.
Oligonucleotide sequences (only one strand shown): A: 50-CGCG
TCATAATTGAGAG CGC-30; D: 50-CGCG TCATAATTCGCGA CGC-30;
E: 50-CGCG TGCTAATTGAGAG CGC-30; B: 50-CGCG TCATCAGC-
GAGAGCGC-30. Experiments were carried out by PAGE on a 10% non-
denaturing gel and 0.5 TBE buffer over 40 min at rt, and analyzed by
staining with SyBrGold (Molecular Probes: 5 mL in 50 mL of TBE) for 10
min, followed by fluorescence visualization. Bottom left: fluorescence
anisotropy titration of a 25 nM solution of TMR-A in the presence of
competing non-specific calf thymus DNA (50 mM) and with increasing
concentrations of BR(Hk)GAGA. The best fit to a 1 : 1 binding model
and the 95% confidence band of the fit (in grey) are also shown.
Bottom right: circular dichroism of a 5 mM solution of BR(Hk)GAGA
(dotted line), of the same solution after the addition of 1 equiv. of
ZnSO4 (dashed line), and after the subsequent addition of 1 equiv. of
Chemical Science Edge Article
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View Article OnlineTherefore, using as reference the structure of the AT-hook motif
RKPRGRPKK, bound to the PRDII sequence of the IFN-
b promoter (see the ESI†), we designed a new conjugate, BR(Hk)
GAGA, comprising three different DNA binding fragments of
natural TFs (GCN4, AT-hook, GAGA). Whereas individually
these fragments are not functional, they might cooperate to
form a trivalent complex with a target composite DNA.
The construct BR(Hk)GAGA was made following the same
synthetic scheme as described for BR(Gly9)GAGA, involving the
independent synthesis of an electrophilic GCN4/AT-hook
module (BR(Hk)-Br), and its chemoselective coupling with a Cys
side chain of the GAGA fragment not involved in the zinc nger
complexation (see Scheme 3 below and the ESI†). The desired
conjugate was obtained aer reverse-phase HPLC puricationScheme 3 Top: synthesis of the GCN4/AT-hook chimera BR(Hk)-Br.
See Scheme 1 for solid phase peptide synthesis of BR[Lys(O1Pen)]. Also
note that the bromoacetyl unit was introduced in the side chain of the
N-terminal lysine of the AT-hook, using Boc-Lys(Fmoc)-OH as
orthogonal amino acid. Bottom: chemoselective modification of the
GAGA Cys2His2 peptide in solution.
the target dsDNA A (10 mM phosphate buffer pH 7.5 and 100 mM of
NaCl; the contribution of the DNA to the CD spectrum has been
subtracted for clarity).
3300 | Chem. Sci., 2016, 7, 3298–3303in a reasonable overall yield of approximately 10%, and iden-
tied by ESI-MS.
In contrast with the results obtained with our original oli-
goglycine design, incubation of BR(Hk)GAGA with a ds-oligo-
nucleotide featuring a composite sequence comprising the
binding sites for the GCN4, the AT-hook, and the GAGA frag-
ment (dsDNA A), led to clear EMSA slow-migrating bands (Fig. 3
top, panel a). This is fully consistent with the formation of
a highly-stable peptide–DNA complex. However, incubation of
BR(Hk)GAGA with a control DNA that does not contain the
consensus GAGA binding site (dsDNA D), shows faint bands
that indicate the formation of low-affinity complexes, presum-
ably arising from weak binary interactions involving the GCN4
and the AT-hook modules (Fig. 3 top, panel b).13 Likewise,
incubation with a second control oligonucleotide lacking the
GCN4 binding site (dsDNA E), leads also to faint retardation
bands, and only at high concentrations of the conjugate (Fig. 3
top, panel c). Therefore, these results conrm that the trifunc-
tional construct presents and excellent selectivity for its
composite tripartite site over potential bipartite competitors. A
control oligonucleotide (dsDNA B), lacking the central A/T-rich,
also gave rise to weaker complexes than with the consensusThis journal is © The Royal Society of Chemistry 2016
Fig. 5 Model obtained using MM calculations of the interaction
between the tripartite construct and the target composite DNA
sequence. The image on the right shows the interaction of the three
modules along the DNA axis covering one side of the double helix.
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View Article OnlineDNA A (Fig. 3 top, panel d), although the binding appears to be
better than with DNAs D and E, probably because the highly
charged AT-hook presents stabilizing electrostatic interactions
with the DNA backbone.
In order to quantify the DNA binding of our construct, we
carried out uorescence anisotropy titrations with selected
uorescently-labeled oligonucleotides. Thus, titrations using
a tetramethyl rhodamine (TMR)-labeled ds-oligonucleotide
containing the target composite site (TMR-A) conrmed
formation of a high affinity complex (KDz 28 nM at rt), even in
the presence of excess of competing calf thymus DNA (Fig. 3
bottom le). Importantly, titration with the ds-oligonucleotide
B (TMR-B), which promoted the appearance of electrophoresis
retarded bands at high concentrations, revealed a much weaker
interaction (more than 500 times lower affinity, see the ESI†).
This conrms that in the presence of excess of non-specic
DNA, the designed hybrid shows exquisite selectivity for its
target 13 base-pair composite tripartite binding site
(TCAT$AATT$GAGAG). In agreement with the results obtained
by EMSA, circular dichroism experiments revealed that addition
of 1 equiv. of the target oligonucleotide A to a 5 mM solution of
BR(Hk)GAGA promotes a signicant increase in the ellipticity of
the negative bands at 208 and 222 nm, consistent with the a-
helical folding of the GCN4 BR (Fig. 3, bottom right).23,24
While the relatively large size of the synthetic construct
might hinder its cellular internalization, we reasoned that the
oligocationic character of its basic region and AT-hook units
could be benecial for the cellular transport.25 Indeed,
a preliminary test with mammalian Vero cells using a tetrame-
thylrhodamine (TMR) derivative of BR(Hk)GAGA (see the ESI†),
led to bright emission inside cells, in a pattern consistent with
endosomal localization (Fig. 4).26 This efficient cell internali-
zation opens the door for cellular applications of these peptide
chimeras.
To gain some structural insight in the complex between the
conjugate BR(Hk)GAGA and the target DNA, we carried out
a computational study using molecular mechanics (MM)
calculations with the obminimize utility script of OpenBabel
2.3.1,27 and the UFF force eld.28 Building on the structural data
available for the DNA interaction of the parent GCN4 and GAGA
proteins, we obtained a model for the interaction of the
conjugate with the target sequence: TCAT$AATT$GAGAG. TheFig. 4 Fluorescence micrography of Vero cells. Brightfield images are
superimposed to the red emission channel after incubation with 5 mM
TMR-BR(Hk)GAGA for 30 min at 37 C.
This journal is © The Royal Society of Chemistry 2016resulting model is fully consistent with a tripartite major–
minor–major groove interaction that involves a relatively large
binding surface covering one face of the DNA (see Fig. 5). This
type of non-natural DNA binding has not been previously
described, and its discovery should open new and important
opportunities in the eld.Conclusions
In summary, we have developed a novel DNA binding motif
consisting of two DNA binding fragments of natural TFs con-
nected via an AT-hook linker, which allows the selective recog-
nition of designed, extended DNA sequences (up to 13 bp). The
success of this design relies on the ability of the AT-hook moiety
to act as a bidentate minor groove-anchoring device that
delivers the DNA binding TF fragments to appropriate positions
for insertion in their respective major grooves. The peptidic
nature of the AT-hook allowed an easy installation of each of the
DNA binding peptides at the C- and N-terminus of the anchor.
The construct represents the rst demonstration of an
engineered synthetic DNA binder that reaches two consecutive
major grooves across the minor groove. The tripartite (major–
minor–major groove) recognition introduces a novel DNA
binding motif that lacks a natural counterpart. This approach
promises to be applicable to other DNA binding TF fragments
addressing different sites, and introduces a novel way of tar-
geting specic and long DNA sequences.Acknowledgements
We are thankful for the support given by the Spanish grants
SAF2013-41943-R, CTQ2013-43264-R and CTQ2013-49317-EXP,
the Xunta de Galicia GRC2013-041, the ERDF, and the European
Research Council (Advanced Grant No. 340055). Support of
COST Action CM1105, COST CM1306 and the orfeo-cinqa
network are kindly acknowledged. J. R. thanks the Xunta de
Galicia for her PhD fellowship. All calculations were carried out
at the CESGA. We thank Dr Jose´ Couceiro for his help with the
cell internalization experiments.Chem. Sci., 2016, 7, 3298–3303 | 3301
Chemical Science Edge Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
5 
Fe
br
ua
ry
 2
01
6.
 D
ow
nl
oa
de
d 
on
 9
/2
4/
20
20
 1
0:
50
:3
6 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article OnlineNotes and references
1 C. W. Garvie and C. Wolberger, Mol. Cell, 2001, 8, 937.
2 (a) D. S. Latchman, Eukaryotic Transcription Factors, Elsevier,
London, 2004; (b) M. Ptashne, A Genetic Switch, Cell Press &
Blackwell, 1992.
3 (a) H. C. Nelson, Curr. Opin. Genet. Dev., 1995, 5, 180; (b)
R. Moretti and A. Z. Ansari, Biochimie, 2008, 90, 1015; (c)
D. J. Segal and C. F. Barbas, Curr. Opin. Chem. Biol., 2000,
4, 34; (d) L. Chen, Curr. Opin. Struct. Biol., 1999, 9, 48.
4 C. Vinson, A. Acharya and E. J. Taparowsky, Biochim. Biophys.
Acta, 2006, 4, 1759.
5 A. Klug, Ann. Rev. Biochem., 2010, 79, 213.
6 (a) N. M. Luscombe, S. E. Austin, H. M. Berman and
J. M. Thornton, Genome Biol., 2000, 1, 1; (b) B. F. Luisi,
W. X. Xu, Z. Otwinowski, L. P. Freedman, K. R. Yamamoto
and P. B. Sigler, Nature, 1991, 352, 497.
7 (a) M. E. Va´zquez, A. M. Caaman˜o and J. L. Mascaren˜as,
Chem. Soc. Rev., 2003, 32, 338; (b) E. Pazos, J. Mosquera,
M. E. Va´zquez and J. L. Mascaren˜as, ChemBioChem, 2011,
12, 1958; (c) C. Y. Majmudar and A. K. Mapp, Curr. Opin.
Chem. Biol., 2005, 9, 467.
8 (a) P. P. Pandol, Oncogene, 2001, 20, 3116; (b) R. Pollock,
M. Giel, K. Linher and T. Clackson, Nat. Biotechnol., 2002,
20, 729; (c) C. Denison and T. Kodadek, Chem. Biol., 1998,
5, R129; (d) A. K. Mapp, Org. Biomol. Chem., 2003, 1, 2217.
9 (a) J. W. Højfeldt, A. R. Van Dyke and A. K. Mapp, Chem. Soc.
Rev., 2011, 40, 4286; (b) H.-D. Arndt, K. E. Hauschild,
D. P. Sullivan, K. Lake, P. B. Dervan and A. Z. Ansari, J. Am.
Chem. Soc., 2003, 125, 13322.
10 (a) N. J. Zondlo and A. Schepartz, J. Am. Chem. Soc., 1999,
121, 6938; (b) J. K. Montclare and A. Schepartz, J. Am.
Chem. Soc., 2003, 125, 3416; (c) M. Zhang, B. Wu, J. Baum
and J. W. Taylor, J. Pept. Res., 2000, 55, 398; (d) T. Morii,
S.-I. Sato, M. Hagihara, Y. Mori, K. Imoto and K. Makino,
Biochemistry, 2002, 41, 2177.
11 (a) R. V. Talanian, C. J. McKnight and P. S. Kim, Science,
1990, 249, 769; (b) C. R. Palmer, S. S. Sloan, J. C. Adrian,
B. Cuenoud, D. N. Paolella and A. Schepartz, J. Am. Chem.
Soc., 1995, 117, 8899; (c) M. Ueno, A. Murakami, K. Makino
and T. Morii, J. Am. Chem. Soc., 1993, 115, 12575; (d)
T. Morii, J. Yamane, Y. Aizawa, K. Makino and Y. Sugiura,
J. Am. Chem. Soc., 1996, 118, 10011; (e) T. Morii, Y. Saimei,
M. Okagami, K. Makino and Y. Sugiura, J. Am. Chem. Soc.,
1997, 119, 3649; (f) A. Mazumder, A. Maiti, K. Roy and
S. Roy, ACS Chem. Biol., 2012, 7, 1084; (g) J. Mosquera,
A. Jime´nez-Balsa, V. I. Dodero, M. E. Va´zquez and
J. L. Mascaren˜as, Nat. Commun., 2013, 4, 1874; (h) Y. Ruiz
Garcia, J. Zelenka, Y. V. Pabon, A. Iyer, M. Budeˇsˇ´ınsky,
T. Kraus, C. I. E. Smith and A. Madder, Org. Biomol. Chem.,
2015, 13, 5273; (i) G. A. Bullen, J. H. R. Tucker and
A. F. A. Peacock, Chem. Commun., 2015, 51, 8130; (j)
L. L. G. Carrette, T. Morii and A. Madder, Eur. J. Org.
Chem., 2014, 2883.
12 (a) J. B. Blanco, M. E. Vazquez, L. Castedo and
J. L. Mascaren˜as, ChemBioChem, 2005, 6, 2173; (b)3302 | Chem. Sci., 2016, 7, 3298–3303M. E. Vazquez, A. M. Caaman˜o, J. Martinez-Costas,
L. Castedo and J. L. Mascaren˜as, Angew. Chem., Int. Ed.,
2001, 40, 4723; (c) M. I. Sanchez, J. Mosquera,
M. E. Va´zquez and J. L. Mascaren˜as, Angew. Chem., Int. Ed.,
2014, 53, 9917; (d) J. B. Blanco, O. Va´zquez, J. Mart´ınez-
Costas, L. Castedo and J. L. Mascaren˜as, Chem.–Eur. J.,
2005, 11, 4171; (e) J. B. Blanco, J. Mar´ınez-Costas,
L. Castedo and J. L. Mascaren˜as, Chem. Biol., 2003, 10, 713.
13 J. Rodr´ıguez, J. Mosquera, J. R. Couceiro, M. E. Va´zquez and
J. L. Mascaren˜as, Chem. Sci., 2015, 6, 4767.
14 C. A. Gersbach, T. Gaj and C. F. Barbas III, Acc. Chem. Res.,
2014, 47, 2309.
15 (a) P. B. Dervan and B. S. Edelson, Curr. Opin. Struct. Biol.,
2003, 13, 284; (b) J. W. Trauger, E. E. Baird and
P. B. Dervan, Chem. Biol., 1996, 3, 369; (c) J. J. Kelly,
E. E. Baird and P. B. Dervan, Proc. Natl. Acad. Sci. U. S. A.,
1996, 93, 6981.
16 R. V. Talanian, C. J. McKnight, R. Rutkowski and P. S. Kim,
Biochemistry, 1992, 31, 6871.
17 A. Iyer, D. Van Lysebetten, Y. Ruiz Garc´ıa, B. Louage, B. G. De
Geest and A. Madder, Org. Biomol. Chem., 2015, 13, 3856.
18 (a) O. Vazquez, M. E. Vazquez, J. B. Blanco-Canosa,
L. Castedo and J. L. Mascaren˜as, Angew. Chem., Int. Ed.,
2007, 46, 6886; (b) M. I. Sa´nchez, O. Vazquez,
M. E. Va´zquez and J. L. Mascaren˜as, Chem.–Eur. J., 2013,
19, 9923.
19 (a) T. E. Ellenberger, C. J. Brandl, K. Struhl and
S. C. Harrison, Cell, 1992, 71, 1223 (PDB ID: 1YSA); (b)
P. Ko¨ning and T. J. Richmond, J. Mol. Biol., 1993, 233, 139.
20 J. G. Omichinski, P. V. Pedone, G. Felsenfeld,
A. M. Gronenborn and G. M. Clore, Nat. Struct. Biol., 1997,
4, 123 (PDB ID: 1YUI).
21 J. Rodr´ıguez, J. Mosquera, O. Va´zquez, M. E. Va´zquez and
J. L. Mascaren˜as, Chem. Commun., 2014, 50, 2258.
22 (a) J. R. Huth, C. A. Bewley, M. S. Nissen, J. N. Evans,
R. Reeves, A. M. Gronenborn and G. M. Clore, Nat. Struct.
Mol. Biol., 1997, 4, 657 (PDB ID: 2EZD and 2EZF); (b)
E. Fonfr´ıa-Subiro´s, F. Acosta-Reyes, N. Saperas, J. Pous,
J. A. Subirana and J. L. Campos, PLoS One, 2012, 7, e37120
(PDB ID: 3UXW).
23 A. D. Frankel, J. M. Berg and C. O. Pabo, Proc. Natl. Acad. Sci.
U. S. A., 1987, 84, 4841.
24 A. Jime´nez, E. Pazos, B. Mart´ınez-Albardonedo,
J. L. Mascaren˜as and M. E. Vazquez, Angew. Chem., Int. Ed.,
2012, 51, 8825.
25 (a) F. Milletti, Drug Discovery Today, 2012, 17, 85; (b)
B. Gupta, T. S. Levchenko and V. P. Torchilin, Adv. Drug
Delivery Rev., 2005, 57, 637; (c) E. A. Goun, T. H. Pillow,
L. R. Jones, J. B. Rothbard and P. A. Wender,
ChemBioChem, 2006, 7, 149; (d) J. Mosquera, M. I. Sa´nchez,
J. Valero, J. de Mendoza, M. E. Va´zquez and
J. L. Mascaren˜as, Chem. Commun., 2015, 51, 4811; (e)
O. Va´zquez, J. B. Blanco-Canosa, M. E. Va´zquez,
J. Mart´ınez Costas, L. Castedo and J. L. Mascaren˜as,
ChemBioChem, 2008, 9, 2822.
26 A number of strategies are available for promoting
endosomal escape of internalized compounds: (a) A. Erazo-This journal is © The Royal Society of Chemistry 2016
Edge Article Chemical Science
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
5 
Fe
br
ua
ry
 2
01
6.
 D
ow
nl
oa
de
d 
on
 9
/2
4/
20
20
 1
0:
50
:3
6 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article OnlineOliveras, N. Muthukrishnan, R. Baker, T. Y. Wang and
J. P. Pellois, Pharmaceuticals, 2012, 5, 1177; (b) A. Erazo-
Oliveras, K. Najjar, L. Dayani, T.-Y. Wang, G. A. Johnson
and J.-P. Pellois, Nat. Methods, 2014, 11, 861.This journal is © The Royal Society of Chemistry 201627 N. M. O'Boyle, M. Banck, C. A. James, C. Morley,
T. Vandermeersch and G. R. Hutchison, J. Cheminf., 2011,
3, 33.
28 A. K. Rappe, C. J. Casewit, K. S. Colwell, W. A. Goddard III
and W. M. Skiff, J. Am. Chem. Soc., 1992, 114, 10024.Chem. Sci., 2016, 7, 3298–3303 | 3303
